April 9, 2018
MPN research

ASH Partners with UNC, a ClinGen grantee to Curate Genomic data for Blood Research

Publisher’s Note: My source at the American Society of Hematology (ASH) informed me that “initially MPNs aren’t going to be a primary focus, however, we expect […]
March 9, 2018
MPN cells

Ruxolitinib Metformin combo: A Possible Alternative Treatment for Myeloproliferative Neoplasm Patients

Metformin demonstrates antileukemic activity and may have clinical implications for the treatment of myeloproliferative neoplasms (MPN) in combination with ruxolitinib, according to a study published in Cell Death & […]
February 22, 2018

How MPN Blood Cancers outsmart the Immune System

AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE Researchers have discovered how some of the blood cancers known as myeloproliferative neoplasms (MPNs) evade the immune system.  Their […]
February 1, 2018
clinical trial in myelofibrosis

Imago BioSciences gets FDA Approval of IND Application for Treatment of Myelofibrosis, IMG-7289 in Clinical Trials

Imago BioSciences, a clinical-stage pharmaceutical company developing novel therapies for hematological and inflammatory diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted their […]
January 8, 2018
Celgene MPN drug Fedratinib

Celgene Acquires Impact Biomedicines, Adding Myeloproliferative Neoplasm Drug Fedratinib to Its Pipeline

Celgene Corporation (NASDAQ:CELG) and Impact Biomedicines today announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for […]
December 27, 2017
Dr Mascarenhas presenting at ASH 2017 on Nutlin

ASH 2017 Nutlin Antagonist Shows Activity in Polycythemia Vera

The investigational Nutlin family antagonist idasanutlin demonstrated significant activity and was well tolerated after multiple cycles of exposure in patients with refractory polycythemia vera (PV). Data […]
WordPress Security